Top View
- Drug Class Review Newer Anticonvulsant Agents 28:12:92 Anticonvulsants, Other
- PRAC Agenda 02-05 September 2019
- Antiepileptic Drugs in Critically Ill Patients Salia Farrokh1* , Pouya Tahsili-Fahadan2,4, Eva K
- Antiepileptic Drug Treatment of Generalised Tonic–Clonic Seizures: An
- New Antiepileptic Drugs
- Appendix B - Product Name Sorted by Applicant
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Pharmacology of Antiepileptic Drugs
- PDL)/Non-Preferred Drug List (NPDL
- Effect of Perampanel Or Amantadine Treatment on Pilocarpine Rat
- FYCOMPA (Perampanel) Tablets, for Oral Use Behavior (5.2) Initial U.S
- Novel Antiepileptic Drugs
- Perampanel (Fycompa) National Drug Monograph May 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- FYCOMPA (Perampanel)
- Attachment: Product Information: Perampanel Hemisesquihydrate
- Advances and Limitations in Pharmacotherapy of Epilepsy
- Perampanel) (Perampanel) Tablets Oral Suspension What Is the Most Important Information I Should Know About FYCOMPA? 1
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Potential Protein-Binding Displacement Interactions with Perampanel an in Vitro Analysis
- The AMPA Receptor As a Therapeutic Target in Epilepsy: Preclinical and Clinical Evidence
- Pharmacological Discrimination of Effects of MK801 on Thalamocortical, Mesothalamic, and Mesocortical Transmissions
- List of Scheduling Actions, Controlled Substances And
- Pharmaabkommen A1 E
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- Probenecid for Use in Treating Epileptic Diseases, Disorders Or Conditions
- Appendix a - Product Name Index
- USP Category USP Class Example Part D Eligible Drugs* Salt/Ester
- Fycompa, INN-Perampanel
- Use of Perampanel for Refractory Seizures in Pediatric Patients Marcia L
- USP Medicare Model Guidelines V7.0 (With Example Part D Drugs)
- Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting
- Product Monograph
- Silent Synapse Activation in Epilepsy
- Title 21 Food and Drugs Part 1300 to End
- Therapeutic and Toxic Blood Concentrations of More Than 1100 Drugs and Other Xenobiotics
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Pharmacodynamic and Pharmacokinetic Interactions of Perampanel
- Controlled Substances
- MEDICATION GUIDE FYCOMPA® (Fī-COM-Puh)
- AHFS Pharmacologic-Therapeutic Classification System
- Discovery and Characterization of AMPA Receptor Modulators Selective for TARP-Γ8
- Radiosynthesis and Preliminary PET Evaluation of 18F-Labeled 2-(1-(3
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Interactions with PBC Agents
- The Following Documentation Is an Electronically‐ Submitted Vendor
- Annex I Summary of Product Characteristics
- Perampanel Efficacy and Tolerability with Enzyme-Inducing Aeds in Patients with Epilepsy
- Preclinical Models of Traumatic Brain Injury: Emerging Role of Glutamate in the Pathophysiology of Depression
- Ethanol 40 L-Glutamic Acid 39 Zonisamide 30 Picrotoxin 22
- Pharmaceuticals and Medical Devices Safety Information No
- Epilepsy (1 of 26)
- Ionotropic Glutamate Receptors in Epilepsy: a Review Focusing on AMPA and NMDA Receptors
- Synergistic Effect of Perampanel and Temozolomide in Human Glioma Cell Lines
- N202-834S005 Perampanel Clinical PREA
- Perampanel, an AMPAR Antagonist, Alleviates Experimental Intracerebral Hemorrhage‑Induced Brain Injury Via Necroptosis and Neuroinflammation
- 2018 Complete Law Book
- Perampanel but Not Amantadine Prevents Behavioral Alterations and Epileptogenesis in Pilocarpine Rat Model of Status Epilepticus
- HHS Public Access Author Manuscript
- Schedules of Controlled Substances: Submitting Comments
- Australian Public Assessment Report for Perampanel
- Fycompa, INN-Perampanel
- Full Disclosures
- A University of Sussex Phd Thesis Available Online Via Sussex
- Kentucky Controlled Substances by Schedule II-V(*Not All Trade Names Included)
- Perampanel, a Potent AMPA Receptor Antagonist, Protects Against Tetramethylenedisulfotetramine‑Induced Seizures and Lethality in Mice: Comparison with Diazepam
- Package Leaflet: Information for the Patient Fycompa 2 Mg, 4 Mg, 6 Mg, 8 Mg, 10 Mg, and 12 Mg Film-Coated Tablets Perampanel